Sanofi's iGlarLixi: Two Formulations Raise FDA Red Flag On Dosing Errors

Sponsor's plan to market two self-injectable pens with different fixed-ratio concentrations of insulin glargine and lixisenatide may result in patients getting inappropriate dose, FDA says in advisory committee briefing documents that also question clinical utility.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America